Literature DB >> 18725550

Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons.

H Nina Kim1, Robert D Harrington, Stephen E Van Rompaey, Mari M Kitahata.   

Abstract

Protective response rates to hepatitis B (HB) vaccination have been reported as low as 18-62% in HIV-infected persons. The relative importance of various predictors for this poor response has not been fully characterized. In this retrospective cohort study, we examined the relationship between clinical characteristics and vaccine non-response (HB surface antibody <10 IU/L) among patients attending an urban HIV clinic. Among the 97 patients who met the inclusion criteria, 43 (44%) developed a protective antibody response. In multivariate analyses, age >40 years (odds ratio [OR] 3.03 [95% confidence interval [CI], 1.14-8.06]; P = 0.026) and alcohol abuse (OR 4.92 [95% CI, 1.72-20.89]; P = 0.007) were independent predictors of failure to develop vaccine response. In addition, CD4 nadir <200 (OR 7.24 [95% CI, 1.91-27.41]; P = 0.004), rather than CD4 current to vaccination, remained a strong independent risk factor. Patients with HIV viral suppression on highly active antiretroviral therapy had a significantly lower rate of vaccine failure (OR 0.31 [95% CI, 0.11-0.91]; P = 0.033), after adjusting for these other covariates. Our findings underscore the importance of confirming seroconversion after HB vaccination in HIV-infected patients and initiating vaccination early in the course of HIV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18725550      PMCID: PMC2690573          DOI: 10.1258/ijsa.2007.007197

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  36 in total

1.  Electronic human immunodeficiency virus (HIV) clinical reminder system improves adherence to practice guidelines among the University of Washington HIV Study Cohort.

Authors:  Mari M Kitahata; Peter W Dillingham; Nathorn Chaiyakunapruk; Susan E Buskin; Jeffrey L Jones; Robert D Harrington; Thomas M Hooton; King K Holmes
Journal:  Clin Infect Dis       Date:  2003-03-04       Impact factor: 9.079

2.  Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.

Authors:  Deborah Konopnicki; Amanda Mocroft; S de Wit; Francisco Antunes; Bruno Ledergerber; Christine Katlama; K Zilmer; Stefano Vella; Ole Kirk; Jens D Lundgren
Journal:  AIDS       Date:  2005-03-24       Impact factor: 4.177

3.  Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy.

Authors:  Krishanthi S Subramaniam; Robert Segal; Robert H Lyles; Maria C Rodriguez-Barradas; Liise-anne Pirofski
Journal:  J Infect Dis       Date:  2003-02-24       Impact factor: 5.226

4.  Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection.

Authors:  Christoph G Lange; Michael M Lederman; Kathy Medvik; Robert Asaad; Mary Wild; Robert Kalayjian; Hernan Valdez
Journal:  AIDS       Date:  2003-09-26       Impact factor: 4.177

5.  Central memory CD4+ T cell responses in chronic HIV infection are not restored by antiretroviral therapy.

Authors:  Mohamed Elrefaei; Michael D McElroy; Christopher P Preas; Rebecca Hoh; Steven Deeks; Jeffrey Martin; Huyen Cao
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

6.  Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects.

Authors:  Scott E Kellerman; Debra L Hanson; A D McNaghten; Patricia L Fleming
Journal:  J Infect Dis       Date:  2003-08-05       Impact factor: 5.226

7.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).

Authors:  Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

8.  The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men.

Authors:  D P Francis; S C Hadler; S E Thompson; J E Maynard; D G Ostrow; N Altman; E H Braff; P O'Malley; D Hawkins; F N Judson; K Penley; T Nylund; G Christie; F Meyers; J N Moore; A Gardner; I L Doto; J H Miller; G H Reynolds; B L Murphy; C A Schable; B T Clark; J W Curran; A G Redeker
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

9.  Hepatitis A and B vaccination practices for ambulatory patients infected with HIV.

Authors:  Ellen M Tedaldi; Rose K Baker; Anne C Moorman; Kathleen C Wood; Jack Fuhrer; Robert E McCabe; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2004-04-28       Impact factor: 9.079

10.  Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2002-05-10
View more
  21 in total

1.  Dissociation of CD154 and cytokine expression patterns in CD38+ CD4+ memory T cells in chronic HIV-1 infection.

Authors:  Enrique Espinosa; Christopher E Ormsby; Gustavo Reyes-Terán; Robert Asaad; Scott F Sieg; Michael M Lederman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 2.  Hepatitis B virus vaccination in HIV-infected people: A review.

Authors:  François-Xavier Catherine; Lionel Piroth
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

3.  The impact of alcohol on BCG-induced immunity against Mycobacterium tuberculosis.

Authors:  Elizabeth Porretta; Kyle I Happel; Xu S Teng; Alistair Ramsay; Carol M Mason
Journal:  Alcohol Clin Exp Res       Date:  2011-10-20       Impact factor: 3.455

Review 4.  Unsolved problems and future perspectives of hepatitis B virus vaccination.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-06-21       Impact factor: 5.742

5.  Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens.

Authors:  Patricia M Flynn; Coleen K Cunningham; Bret Rudy; Craig M Wilson; Bill Kapogiannis; Carol Worrell; James Bethel; Dina Monte; Kelly Bojan
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

Review 6.  Hepatitis B vaccine by intradermal route in non responder patients: an update.

Authors:  Martina Filippelli; Elena Lionetti; Alessia Gennaro; Angela Lanzafame; Teresa Arrigo; Carmelo Salpietro; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

Review 7.  Liver disease in the HIV-infected individual.

Authors:  Jennifer C Price; Chloe L Thio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

Review 8.  Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

Authors:  Hsin-Yun Sun; Wang-Huei Sheng; Mao-Song Tsai; Kuan-Yeh Lee; Sui-Yuan Chang; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

9.  Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons.

Authors:  Masako Mizusawa; David C Perlman; David Lucido; Nadim Salomon
Journal:  Int J STD AIDS       Date:  2013-08-29       Impact factor: 1.359

Review 10.  Optimal timing of routine vaccination in HIV-infected persons.

Authors:  Heidi M Crane; Shireesha Dhanireddy; H Nina Kim; Christian Ramers; Timothy H Dellit; Mari M Kitahata; Robert D Harrington
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.